Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of real-world data, how ‘big data’ can help physicians understand treatment characteristics, and the future impact of incorporating this data into management of multiple sclerosis.
Questions:
1. Randomized controlled trials are the gold standard for supporting the approval of interventions; what benefits are gained when exploring real-world data for the impact of treatments? (00:15)
2. How can ‘big data’ help physicians understand treatment characteristics in the population of people with multiple sclerosis, and what do you think the most important signals are? (00:56)
3. What evidence exists to support physicians in deciding when to initiate, switch or cease a pharmaceutical intervention? (01:34)
4. What do you see as the future impact of incorporating more real-world data into the understanding of management of multiple sclerosis? (02:26)
The abstract titled ‘Real-World-Evidence (Big data, registries): “game-changer” for regulatory and clinical views on when to start, switch and stop of disease-modifying therapies in MS?’ (Abstract #SYMP02-4) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Melinda Magyari has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
Click here for more content on this topic.
